Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $112.7 million.

  • Tarsus Pharmaceuticals' Cash & Equivalents fell 3602.86% to $112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.7 million, marking a year-over-year decrease of 3602.86%. This contributed to the annual value of $94.8 million for FY2024, which is 5784.83% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Cash & Equivalents of $112.7 million as of Q3 2025, which was down 3602.86% from $96.6 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Cash & Equivalents peaked at $245.4 million during Q2 2022, and registered a low of $66.0 million during Q1 2023.
  • Its 5-year average for Cash & Equivalents is $158.2 million, with a median of $175.0 million in 2022.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Cash & Equivalents skyrocketed by 23261.5% in 2021, and later crashed by 6228.96% in 2023.
  • Tarsus Pharmaceuticals' Cash & Equivalents (Quarter) stood at $171.3 million in 2021, then tumbled by 58.17% to $71.7 million in 2022, then soared by 213.91% to $224.9 million in 2023, then plummeted by 57.85% to $94.8 million in 2024, then rose by 18.88% to $112.7 million in 2025.
  • Its Cash & Equivalents stands at $112.7 million for Q3 2025, versus $96.6 million for Q2 2025 and $175.8 million for Q1 2025.